{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Erythropoietin&page=3",
    "query": {
      "condition": "Erythropoietin",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 169,
    "total_pages": 17,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Erythropoietin&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Erythropoietin&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T19:04:27.655Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01906489",
      "title": "20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anemia",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "AKB-6548",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akebia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "82 Years",
        "sex": "ALL",
        "summary": "18 Years to 82 Years"
      },
      "enrollment_count": 210,
      "start_date": "2013-07-23",
      "completion_date": "2014-09-03",
      "has_results": true,
      "last_update_posted_date": "2022-07-21",
      "last_synced_at": "2026-09-30T19:04:27.655Z",
      "location_count": 47,
      "location_summary": "Glendale, Arizona • Tucson, Arizona • Azusa, California + 44 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01906489"
    },
    {
      "nct_id": "NCT02412449",
      "title": "Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "AKB-6548 tablet, reference formulation given in the fasted state",
          "type": "DRUG"
        },
        {
          "name": "AKB-6548 tablet, test formulation given in the fasted state.",
          "type": "DRUG"
        },
        {
          "name": "AKB-6548 tablet, test formulation given in the fed state",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akebia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 18,
      "start_date": "2015-04",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2018-11-14",
      "last_synced_at": "2026-09-30T19:04:27.655Z",
      "location_count": 1,
      "location_summary": "Kalamazoo, Michigan",
      "locations": [
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02412449"
    },
    {
      "nct_id": "NCT00258440",
      "title": "Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anemia",
        "Fatigue",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "Weekly procrit dosing",
          "type": "DRUG"
        },
        {
          "name": "Interval Dosing",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2003-05",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2017-05-09",
      "last_synced_at": "2026-09-30T19:04:27.655Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00258440"
    },
    {
      "nct_id": "NCT01414075",
      "title": "Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dialysis",
        "Anemia"
      ],
      "interventions": [
        {
          "name": "Roxadustat",
          "type": "DRUG"
        },
        {
          "name": "Oral Iron",
          "type": "DRUG"
        },
        {
          "name": "IV Iron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kyntra Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2011-07-21",
      "completion_date": "2013-01-10",
      "has_results": true,
      "last_update_posted_date": "2021-10-01",
      "last_synced_at": "2026-09-30T19:04:27.655Z",
      "location_count": 3,
      "location_summary": "Northridge, California • Yuba City, California • Detroit, Michigan",
      "locations": [
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Yuba City",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01414075"
    },
    {
      "nct_id": "NCT00313716",
      "title": "Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Anemia",
        "Traumatic Brain Injury"
      ],
      "interventions": [
        {
          "name": "recombinant human erythropoietin, rhEpo",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Claudia Sue Robertson",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2006-04",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2014-09-10",
      "last_synced_at": "2026-09-30T19:04:27.655Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00313716"
    },
    {
      "nct_id": "NCT00416624",
      "title": "Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anemia",
        "Leukemia",
        "Lymphoma",
        "Lymphoproliferative Disorder",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Precancerous Condition",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "darbepoetin alfa",
          "type": "DRUG"
        },
        {
          "name": "epoetin alfa",
          "type": "DRUG"
        },
        {
          "name": "fatigue assessment and management",
          "type": "PROCEDURE"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 239,
      "start_date": "2007-05",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2017-02-10",
      "last_synced_at": "2026-09-30T19:04:27.655Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00416624"
    },
    {
      "nct_id": "NCT02802592",
      "title": "EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cardiac Surgery-CABG",
        "Cardiac Valve Replacement"
      ],
      "interventions": [
        {
          "name": "Epogen",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 4,
      "start_date": "2015-05",
      "completion_date": "2017-02-27",
      "has_results": true,
      "last_update_posted_date": "2019-02-26",
      "last_synced_at": "2026-09-30T19:04:27.655Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02802592"
    },
    {
      "nct_id": "NCT02680574",
      "title": "Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anemia",
        "Non-Dialysis-Dependent Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Vadadustat",
          "type": "DRUG"
        },
        {
          "name": "Darbepoetin alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akebia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1725,
      "start_date": "2016-02",
      "completion_date": "2020-07-31",
      "has_results": true,
      "last_update_posted_date": "2022-06-27",
      "last_synced_at": "2026-09-30T19:04:27.655Z",
      "location_count": 219,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 158 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tuscumbia",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02680574"
    },
    {
      "nct_id": "NCT01378273",
      "title": "Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Extreme Prematurity"
      ],
      "interventions": [
        {
          "name": "Epo",
          "type": "DRUG"
        },
        {
          "name": "Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "24 Weeks",
        "maximum_age": "27 Weeks",
        "sex": "ALL",
        "summary": "24 Weeks to 27 Weeks"
      },
      "enrollment_count": 941,
      "start_date": "2013-12",
      "completion_date": "2020-02-28",
      "has_results": true,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-09-30T19:04:27.655Z",
      "location_count": 19,
      "location_summary": "Little Rock, Arkansas • Gainesville, Florida • Miami, Florida + 14 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01378273"
    },
    {
      "nct_id": "NCT00003600",
      "title": "Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anemia",
        "Breast Cancer",
        "Chronic Myeloproliferative Disorders",
        "Drug/Agent Toxicity by Tissue/Organ",
        "Leukemia",
        "Lung Cancer",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Precancerous Condition",
        "Small Intestine Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "epoetin alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 344,
      "start_date": "1998-12",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2016-07-13",
      "last_synced_at": "2026-09-30T19:04:27.655Z",
      "location_count": 20,
      "location_summary": "Scottsdale, Arizona • Washington D.C., District of Columbia • Peoria, Illinois + 17 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Cedar Rapids",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003600"
    }
  ]
}